Aytu BioScience Inc (AYTU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aytu BioScience Inc (AYTU) has a cash flow conversion efficiency ratio of 0.259x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.67 Million) by net assets ($14.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aytu BioScience Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Aytu BioScience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AYTU total debt and obligations for a breakdown of total debt and financial obligations.
Aytu BioScience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aytu BioScience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cubic Korea Inc
KQ:021650
|
-0.024x |
|
Xali Gold Corp
V:XGC
|
0.030x |
|
Castile Resources Ltd
AU:CST
|
-0.018x |
|
Zodiac Energy Limited
NSE:ZODIAC
|
-0.145x |
|
Censof Holdings Bhd
KLSE:5195
|
0.051x |
|
Lion Industries Corporation Bhd
KLSE:4235
|
-0.061x |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
0.013x |
|
Boundless Bio, Inc. Common Stock
NASDAQ:BOLD
|
-0.093x |
Annual Cash Flow Conversion Efficiency for Aytu BioScience Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aytu BioScience Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Aytu BioScience Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $18.97 Million | $-1.94 Million | -0.102x | -103.94% |
| 2024-06-30 | $27.72 Million | $-1.39 Million | -0.050x | +61.57% |
| 2023-06-30 | $39.36 Million | $-5.13 Million | -0.130x | +79.97% |
| 2022-06-30 | $44.31 Million | $-28.82 Million | -0.651x | -244.67% |
| 2021-06-30 | $137.57 Million | $-25.96 Million | -0.189x | +36.80% |
| 2020-06-30 | $95.02 Million | $-28.37 Million | -0.299x | +84.70% |
| 2019-06-30 | $7.09 Million | $-13.83 Million | -1.951x | -64.34% |
| 2018-06-30 | $13.42 Million | $-15.94 Million | -1.187x | +65.66% |
| 2017-06-30 | $4.00 Million | $-13.83 Million | -3.458x | -227.19% |
| 2016-06-30 | $10.09 Million | $-10.66 Million | -1.057x | -148.75% |
| 2015-06-30 | $15.62 Million | $-6.63 Million | -0.425x | +58.54% |
| 2014-06-30 | $5.37 Million | $-5.50 Million | -1.025x | -401.27% |
| 2013-06-30 | $-110.86K | $-37.70K | 0.340x | -37.35% |
| 2012-06-30 | $-69.72K | $-37.85K | 0.543x | -70.19% |
| 2011-06-30 | $-35.59K | $-64.82K | 1.821x | +133.46% |
| 2010-06-30 | $-55.61K | $-43.38K | 0.780x | -77.28% |
| 2009-06-30 | $-13.58K | $-46.63K | 3.433x | +298.92% |
| 2008-06-30 | $25.96K | $-44.80K | -1.726x | -16.26% |
| 2007-06-30 | $18.81K | $-27.92K | -1.484x | -- |
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more